Close window icon

3 INDICATIONS Otezla® (apremilast) is indicated for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy.

Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.

Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet's Disease. Read less

Read less

Otezla is the first and only oral therapy approved across all severities of adult plaque psoriasis SEE THE DATA

MORE FORMULARY ACCESS THAN EVER BEFORE

Image of 9 out of 10 commercial patients with plaque psoriasis or psoriatic arthritis have preferred access to Otezla with no biologic-step required

COMMERCIALLY INSURED PATIENTS
HAVE PREFERRED ACCESS TO OTEZLA
WITH NO BIOLOGIC STEP FOR
PSORIATIC ARTHRITIS AND MODERATE
TO SEVERE PSORIASIS

~2 OUT OF 3

COMMERCIALLY INSURED PATIENTS HAVE PREFERRED ACCESS TO OTEZLA WITH
NO DMARD STEP OR BIOLOGIC STEP FOR PsA AND MODERATE TO SEVERE PLAQUE PSORIASIS 1,*

*66.3% of commercially insured patients have preferred access to Otezla with no DMARD step or biologic step for PsA and 63.2% of commercially insured patients have preferred access to Otezla with no DMARD step or biologic step for moderate to severe plaque psoriasis.

ENCOURAGE COMMERCIALLY INSURED PATIENTS TO ENROLL IN
THE COMBINED $0 CO-PAY AND BRIDGE PROGRAM FOR OTEZLA

Graphic of the continental United States map set on top of a solid colored circle background

BROAD COVERAGE

Otezla is now covered by ~99% of commercial insurance plans nationally 1,†

Graphic of Otezla Co-Pay card set on top of a solid colored circle background

GREAT AFFORDABILITY

Commercially insured patients can get Otezla for $0 per month with the Otezla Co-Pay Card

Graphic of Otezla's Bridge Program logo set on top of a solid colored circle background

BRIDGE SUPPORT

The Bridge Program offers your commercially insured patients Otezla for free while awaiting coverage approval §

Local coverage may vary. The Otezla Co-Pay Card is for eligible commercially insured patients. Terms, conditions, and program maximums apply. Other restrictions may apply. Please see full Terms and Conditions. This program is not open to patients receiving prescription reimbursement under any federal, state, or government-funded healthcare program. Not valid where prohibited by law. Patients who are not eligible can call 1-844-4OTEZLA to discuss further financial support opportunities. §If the patient’s health plan requires a prior authorization or if patient experiences a delay in obtaining approval for Otezla, patients can qualify for the Bridge to Commercial Coverage Offer and receive Otezla free for up to 12 months while pursuing approval from their health plan. No purchase necessary. Please see full Terms and Conditions.

OTEZLA PROVIDES SUPPORT EVERY STEP OF THE WAY

OTEZLA SUPPORTPLUS™ PROGRAM: DEDICATED SUPPORT FOR YOU, YOUR OFFICE, AND YOUR PATIENTS

Graphic of a computer monitor with a plus sign outline in the center of the screen set on circular background

Office Resources

  • Benefits investigation
  • PA and appeal assistance
  • Assessment of patient eligibility for Medicare coverage
Graphic representation of a woman's head and shoulders set in a circle, which is set on a circle background

Patient Resources

  • Financial support options available for all patients
  • 1:1 tailored support with an Otezla Nurse Partner **
  • Insurance support

OTEZLA NURSE PARTNER PROGRAM

The Otezla Nurse Partner ** program works closely with your new Otezla patients to provide tailored support, including how to get started on Otezla, maintaining a treatment routine, and guiding them to resources based on their individual goals.

Enrollment is simple for your Otezla patients. Encourage them to sign up for Otezla SupportPlus™ to access the Otezla Nurse Partner program today!

**Otezla Nurse Partners are nurses by training, but they are not part of a patient’s treatment team or an extension of their doctor’s office. Patients will be referred to their doctor’s office for clinical advice.

Graphic for Otezla Nurse Partner program

WHETHER IT’S YOU, YOUR OFFICE, OR YOUR PATIENTS, GET ANSWERS
TO QUESTIONS BY CALLING OTEZLA SUPPORTPLUS™ AT

1-844-4OTEZLA

(1-844-468-3952)

8AM-8PM ET, MONDAY-FRIDAY, OR VISIT OTEZLAPRO.COM UNDER RESOURCES

 

DMARD, disease-modifying antirheumatic drug; PA, prior authorization; PsA, psoriatic arthritis.

Accordion icon

IMPORTANT SAFETY INFORMATION

Contraindications

  • Otezla is contraindicated in patients with a known hypersensitivity to apremilast or to any of the excipients in the formulation

Warnings and Precautions

  • Hypersensitivity: Hypersensitivity reactions, including angioedema and anaphylaxis, have been reported during postmarketing surveillance. If signs or symptoms of serious hypersensitivity reactions occur, discontinue Otezla and institute appropriate therapy
  • Diarrhea, Nausea, and Vomiting: Cases of severe diarrhea, nausea, and vomiting were associated with the use of Otezla. Most events occurred within the first few weeks of treatment. In some cases, patients were hospitalized. Patients 65 years of age or older and patients taking medications that can lead to volume depletion or hypotension may be at a higher risk of complications from severe diarrhea, nausea, or vomiting. Monitor patients who are more susceptible to complications of diarrhea or vomiting; advise patients to contact their healthcare provider. Consider Otezla dose reduction or suspension if patients develop severe diarrhea, nausea, or vomiting
  • Depression: Carefully weigh the risks and benefits of treatment with Otezla for patients with a history of depression and/or suicidal thoughts/behavior, or in patients who develop such symptoms while on Otezla. Patients, caregivers, and families should be advised of the need to be alert for the emergence or worsening of depression, suicidal thoughts or other mood changes, and they should contact their healthcare provider if such changes occur
    • Plaque Psoriasis: Treatment with Otezla is associated with an increase in depression. During clinical trials in patients with moderate to severe plaque psoriasis, 1.3% (12/920) of patients reported depression compared to 0.4% (2/506) on placebo. Depression was reported as serious in 0.1% (1/1308) of patients exposed to Otezla, compared to none in placebo-treated patients (0/506). Suicidal behavior was observed in 0.1% (1/1308) of patients on Otezla, compared to 0.2% (1/506) on placebo. One patient treated with Otezla attempted suicide; one patient on placebo committed suicide
    • Psoriatic Arthritis: Treatment with Otezla is associated with an increase in depression. During clinical trials, 1.0% (10/998) reported depression or depressed mood compared to 0.8% (4/495) treated with placebo. Suicidal ideation and behavior was observed in 0.2% (3/1441) of patients on Otezla, compared to none in placebo-treated patients. Depression was reported as serious in 0.2% (3/1441) of patients exposed to Otezla, compared to none in placebo-treated patients (0/495). Two patients who received placebo committed suicide compared to none on Otezla
    • Behçet’s Disease: Treatment with Otezla is associated with an increase in depression. During the clinical trial, 1% (1/104) reported depression or depressed mood compared to 1% (1/103) treated with placebo. No instances of suicidal ideation or behavior were reported in patients treated with Otezla or treated with placebo
  • Weight Decrease: Monitor body weight regularly; evaluate unexplained or clinically significant weight loss, and consider discontinuation of Otezla
    • Plaque Psoriasis: Body weight loss of 5-10% occurred in 12% (96/784) of patients with moderate to severe plaque psoriasis treated with Otezla and in 5% (19/382) of patients treated with placebo. Body weight loss of ≥10% occurred in 2% (16/784) of patients treated with Otezla compared to 1% (3/382) of patients treated with placebo
    • Psoriatic Arthritis: Body weight loss of 5-10% was reported in 10% (49/497) of patients taking Otezla and in 3.3% (16/495) of patients taking placebo
    • Behçet’s Disease: Body weight loss of >5% was reported in 4.9% (5/103) of patients taking Otezla and in 3.9% (4/102) of patients taking placebo
  • Drug Interactions: Apremilast exposure was decreased when Otezla was co-administered with rifampin, a strong CYP450 enzyme inducer; loss of Otezla efficacy may occur. Concomitant use of Otezla with CYP450 enzyme inducers (e.g., rifampin, phenobarbital, carbamazepine, phenytoin) is not recommended

Adverse Reactions

  • Plaque Psoriasis: The most common adverse reactions (≥5%) are diarrhea, nausea, upper respiratory tract infection, and headache, including tension headache. Overall, the safety profile of Otezla in patients with mild to moderate plaque psoriasis was consistent with the safety profile previously established in adult patients with moderate to severe plaque psoriasis
  • Psoriatic Arthritis: The most common adverse reactions (≥5%) are diarrhea, nausea, and headache
  • Behçet’s Disease: The most common adverse reactions (≥10%) are diarrhea, nausea, headache, and upper respiratory tract infection

Use in Specific Populations

  • Otezla has not been studied in pregnant women. Advise pregnant women of the potential risk of fetal loss

Please click here for the full Prescribing Information.

INDICATIONS

Otezla® (apremilast) is indicated for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy.

Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.

Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.

Reference: 1. Data on file, Amgen Inc.